본문 바로가기
KERD
논문KCI 등재

바이오헬스기업에서 외향형 개방형혁신의 적합한 협력관리는 무엇인가? - 협력대상의 조절효과 -

What is the Appropriate Cooperation Management of Inside-Out Open Innovation in a Bio-Health Company? - A Moderating Effect of Cooperation Partners -

0

조회

0

다운로드

5

인용

0

참고문헌

키워드

초록

본 연구는 바이오헬스 기업들이 외향형 개방형혁신을 추진하고자 할 때, 외부협력 파트너 유형에 따라서 적절한 협력관리가 무엇인지를 밝히기 위하여 ‘외향형 개방형 혁신 → 협력관리(통제 vs. 상호조정) → 신제품 성과 관계’를 규명하였다. 또한, 외부 파트너 유형(산업내 파트너 vs. 산업밖 파트너)에 따른 조절효과를 살펴보았다. 그 결과 다음과 같은 결과가 도출되었다. 첫째, 바이오헬스 기업들의 외향형 개방형혁신은 상호조정 및 통제 기반의 협력관리 모두에 긍정적인 영향을 미치는 것으로 나타났다. 둘째, 통제를 기반으로 한 협력관리가 신제품 성과에 긍정적 영향을 미치는 것으로 나타났다. 셋째, 협력대상(산업내 파트너 vs. 산업밖 파트너)의 조절효과를 분석한 결과, 바이오헬스기업들이 외향형 개방형혁신을 수행할 때 산업 밖 파트너를 대상으로 통제기반의 협력관리를 강조하는 것이 효과적인 것으로 나타났다.

Abstract

When a bio-health company wants to promote external open innovation, appropriate cooperation management according to the type of external cooperation partner was analyzed through 'Inside-out open innovation → cooperation management (control vs. mutual adjustment) → new product performance relationship'. In addition, the moderating effect according to the type of external partner (inside of the industry vs. outside of the industry) was investigated. As a result, the following results were derived. First, it was found that in-side out open innovation of bio-health companies had a positive effect on both mutual coordination and control-based cooperation management. Second, control-based coordination management was found to have a positive effect on the performance of new products. Third, as a result of analyzing the moderating effect of cooperation partners (inside of the industry vs. outside of the industry), When bio-health companies engage inside-out open innovation, it was found that it is effective to conduct control-based cooperation management with partners outside the industry.

참고문헌 (60)

  1. 김수진, "바이오벤처기업의 기술지향성과 시장지향성이 신제품성과에 영향을 미치는 요인에 관한 연구", 연세경영연구, 57(1), pp.55~83 (2020), 경영연구소
  2. 김원덕, "유통업체와 금융업체의 전략적 제휴에 관한 연구-은행 및 보험업체와의 제휴를 중심으로", 한국유통과학회 학술대회 논문집, pp.735~743 (2006)
  3. 김지대, "조직문화가 신제품개발 관리에 미치는 영향", 경영학연구, 36(1), pp.133~157 (2007), 한국경영학회
  4. 김종배, "신제품 개발과정에서의 조직간 협력이 성과에 미치는 영향", 상품학연구, 34(4), pp.107~114 (2016), 한국상품학회[DOI]
  5. 한국의 바이오의료 신산업 발전전략 제언, "김한해", 한국과학기술기획평가원, ~ (2018)
  6. 메디컬 옵저버, "또 한미약품 쇼크?: 1조원 기술수출 삐끗, 2019, 7월 15일", ~ (2019)
  7. 문혜선, "대학-기업 간 연구개발협력에서 불확실성, 협력 관리시스템, 기업의 혁신 성과 간 관계에 대한 연구", 경영학연구, 43(2), pp.415~441 (2014), 한국경영학회
  8. 서용준, "창업초기기업 개방형 혁신활동의 조절효과 연구", 경영연구, 36(1), pp.75~85 (2021), 한국산업경영학회[DOI]
  9. 이익근, "바이오헬스기업의 신제품개발전략이 개방형혁신활동과 신제품성과에 미치는 영향", 기술경영, 6(3), pp.61~82 (2021), 국가미래기술경영연구소[DOI]
  10. 장완진, "개방형 혁신 전략에서 개방성(openness)과 전유 전략의 관계에 대한 연구: 국내 중소 제조업을 중심으로", 산업혁신연구, 34(4), pp.21~46 (2018), 산업개발연구소[DOI]
  11. 정상은, "협업을 통한 신제품 개발과 커뮤니케이션이 성과에 미치는 영향 연구", 한국산학기술학회논문지, 21(10), pp.558~566 (2020), 한국산학기술학회[DOI]
  12. 조영복, "기업의 개방형 혁신이 공유가치창출에 미치는 영향", 사회적가치와 기업연구, 9(2), pp.131~148 (2016), 사단법인 사회적기업학회
  13. 천병년, "공공바이오 클러스터의 지원체제가 경영성과에 미치는 영향", 기술경영, 5(3), pp.151~172 (2020), 국가미래기술경영연구소[DOI]
  14. 최한실, "바이오 헬스케어 산업", 바이오경제연구, 2(2), pp.23~67 (2019)
  15. 추승엽, "기업가적 지향성과 경영성과 간 관계: 조직규모에 따른 신제품개발의 조건부 간접효과", 벤처창업연구, 15(3), pp.133~144 (2020), 한국벤처창업학회[DOI]
  16. 채수찬, "카이스트, 바이오헬스의 미래를 말하다" (2020), 율곡출판사
  17. 한재훈, "개방형 혁신(Open Innovation)과 기술혁신 성과 : 개방협력 대상의 다양성, 기술 보호 및 창의성에 대한 경영자의 역할을 중심으로", 전문경영인연구, 16(1), pp.41~60 (2013), 한국전문경영인학회
  18. Bamford, J., "Managing an alliance portfolio", The McKinsey Quarterly, 3(8), pp.25~35 (2002)
  19. Beamish, P. W., "Keeping international joint ventures stable and profitable", Long Range Planning, 28(3), pp.2~36 (1995)
  20. Belderbos, R., "Cooperative R&D and firm performance", Research policy, 33(10), pp.1477~1492 (2004)
  21. Bigliardi, B., "The past, present and future of open innovation", European Journal of Innovation Management (2021)
  22. Chesbrough, H. W., "Open innovation: The new imperative for creating and profiting from technology" (2003), Harvard Business School Press
  23. Chesbrough, H., "Beyond high tech: early adopters of open innovation in other industries", R&d Management, 36(3), pp.229~236 (2006)
  24. Chesbrough, H. W., "Why companies should have open business models", MIT Sloan management review, 48(2), pp.22~ (2007)
  25. Chesbrough, H. W., "Open Business Models: How to Thrive in the Innovation Landscape" (2006), Harvard Business School Press
  26. Chesbrough, H., "The Future of Open Innovation: IRI Medal Address The future of open innovation will be more extensive, more collaborative, and more engaged with a wider variety of participants", Research-Technology Management, 60(6), pp.29~35 (2017)
  27. Chin, W. W., "Adoption Intention in GSS: Importance of Beliefs", Data Base for Advances in Information Systems, 26, pp.42~64 (1995)
  28. Dahlander, L., "How open is innovation?", Research policy, 39(6), pp.699~709 (2010)
  29. Das, T. K., "A resource-based theory of strategic alliances", Journal of management, 26(1), pp.31~61 (2000)
  30. DiMasi, J. A., "The cost of biopharmaceutical R&D: is biotech different?", Managerial and decision Economics, 28(4-5), pp.469~479 (2007)
  31. Di Minin, A., "Fiat: open innovation in a downturn (1993–2003)", California Management Review, 52(3), pp.132~159 (2010)
  32. Fornell, C., "Evaluating Structural Equation Models with Unobservable Variables and Measurement Error", Journal of Marketing Research, 18(1), pp.39~50 (1981)
  33. Forrest, J. E., "Strategic alliances between large and small research intensive organizations: experiences in the biotechnology industry", R&D Management, 22(1), pp.041~054 (1992)
  34. Gassmann, O., "Opening up the innovation process: Towards an agenda", R & d Management, 36(3), pp.223~228 (2006)
  35. Gassmann, O., "Towards a theory of open innovation:three core process archetypes" (2004)
  36. Gassmann, O., "Organizing pharmaceutical innovation: from science‐based knowledge creators to drugoriented knowledge brokers", Creativity and Innovation Management, 14(3), pp.233~245 (2005)
  37. Geletkanycz, M. A., "The external ties of top executives: Implications for strategic choice and performance", Administrative science quarterly, pp.654~681 (1997)
  38. Hair, J, F, "A primer on partial least squares structural equation modeling (PLS-SEM)" (2017), Sage
  39. Hair, J. F., "Multivariate Data Analysis with Readings" (2006), Macmillan Publishing Company
  40. Ireland, R. D., "Alliance management as a source of competitive advantage", Journal of management, 28(3), pp.413~446 (2002)
  41. Jarillo, J. C., "On strategic networks", Strategic management journal, 9(1), pp.31~41 (1988)
  42. Kim, Y., "Choosing between international technology licensing partners: An empirical analysis of US biotechnology firms", Journal of Engineering and Technology Management, 26(1-2), pp.57~72 (2009)
  43. Koza, M., "Managing partnerships and strategic alliances: raising the odds of success", European Management Journal, 18(2), pp.146~151 (2000)
  44. Lee, J. H., "Factors affecting pricing in patent licensing contracts in the biopharmaceutical industry", Sustainability, 10(9), pp.3143~ (2018)
  45. Lee, J. H., "Evaluating determinant priority of license fee in biotech industry", Journal of Open Innovation: Technology, Market, and Complexity, 4(3), pp.30~ (2018)
  46. Lokshin, B., "The bumpy road of technology partnerships: Understanding causes and consequences of partnership mal-functioning", Research Policy, 40(2), pp.297~308 (2011)
  47. Miotti, L., "Co-operative R&D: why and with whom?:An integrated framework of analysis", Research policy, 32(8), pp.1481~1499 (2003)
  48. Morandi, V., "The management of industry–university joint research projects: how do partners coordinate and control R&D activities?", The Journal of Technology Transfer, 38(2), pp.69~92 (2013)
  49. Muthusamy, S. K., "Does power sharing matter? The role of power and influence in alliance performance", Journal of Business Research, 59(7), pp.811~819 (2006)
  50. Nishimura, J., "R&D portfolios and pharmaceutical licensing", Research policy, 43(7), pp.1250~1263 (2014)
  51. Park, S. H., "Interfirm rivalry and managerial complexity: A conceptual framework of alliance failure", Organization science, 12(1), pp.37~53 (2001)
  52. Paul, S. M., "How to improve R&D productivity: the pharmaceutical industry’s grand challenge", Nature Reviews Drug Discovery, 9(3), pp.203~ (2010)
  53. Reger, G., "How R&D is coordinated in Japanese and European multinationals", R&D Management, 29(1), pp.71~88 (1999)
  54. Rojas, M. G. A., "Innovation and network multiplexity: R&D and the concurrent effects of two collaboration networks in an emerging economy", Research Policy, 47(6), pp.1111~1124 (2018)
  55. Ruckman, K., "Why do some patents get licensed while others do not?", Industrial and Corporate Change, 26(4), pp.667~688 (2017)
  56. Schilling, M. A., "Strategic management of technological innovation" (2019), McGraw-Hill Education
  57. Tomlinson, P. R., "Co-operative ties and innovation: Some new evidence for UK manufacturing", Research policy, 39(6), pp.762~775 (2010)
  58. Van de Vrande, V., "Open innovation in SMEs: Trends, motives and management challenges", Technovation, 29(6-7), pp.423~437 (2009)
  59. West, J., "Open innovation: The next decade", Research policy, 43(5), pp.805~811 (2014)
  60. Williamson, O. E., "Markets and hierarchies: analysis and antitrust implications: a study in the economics of internal organization", University of Illinois at Urbana-Champaign's Academy for Entrepreneurial Leadership Historical Research Reference in Entrepreneurship, ~ (1975)

관련 논문AI추천

이 간행물의 다른 논문 (6건)